BioMap

BioMap is a pioneering life sciences AI company focused on decoding biological complexity through large-scale foundation models. The company develops and deploys AI-driven discovery systems that serve a broad range of life science organizations, including multinational corporations, Fortune Global 500 companies, academic institutions, and industry leaders across drug development, synthetic biology, and frontier research.

At the core of BioMap's offering is xTrimo, the world's first 268-billion-parameter life science AI foundation model. xTrimo V4 is built on raw biological data and demonstrates deep understanding of the underlying principles governing DNA, RNA, proteins, cells, chemistry, multi-cells, and biosystems. It enables cross-modal reasoning on complex and previously unknown biological problems, achieving more than 300 State-of-the-Art (SOTA) model performances across over 20 scientific fields.

xTrimo Foundation Model: Core Pillars

• Data: An industry-leading stack for multi-modal biological intelligence, providing the foundation for comprehensive biological understanding.
• Algorithms: Multi-modal, ultra-long, expert-driven modeling approaches that enable sophisticated reasoning across biological domains.
• Experimentation: A high-throughput, closed-loop intelligent experiment system that connects computational predictions with real-world validation.
• Infrastructure: A bio-computing engine with global multi-cloud deployment, ensuring scalable and flexible access to computational resources.

BioMap OS: AI-Driven Life Science Discovery System

• BioMap OS is a dry-wet closed-loop life science discovery system powered by xTrimo foundation models, designed to enhance data insight, parameter optimization, and de novo design.
• The platform integrates multiple functional modules into a single system, including knowledge aggregation, predictive design, experimental control, and model training.
• It bridges wet and dry laboratory workflows, enabling full-cycle data accumulation and analysis to significantly improve R&D efficiency and success rates.
• BioMap OS supports modular and flexible deployment, available as models, software, or a complete integrated system.
• The system features configurable professional components and supports both cloud and on-premises deployment options.
• Clients can access BioMap OS through system licensing for independent discovery workflows or engage BioMap directly for discovery services such as protein and antibody discovery.

Industry Solutions and Verticals

• Antibody and Protein Discovery: BioMap OS enables data-driven de novo protein design and multi-objective optimization through an integrated AI and experimental closed loop, addressing the challenge of optimizing multiple properties across vast protein design spaces. This has been validated across more than 40 advanced programs, delivering precise epitope control and high-performance antibody and protein candidates.
• Innovative Therapies and Precision Medicine: Solutions targeting novel target discovery, innovative drug development, and personalized therapeutic approaches.
• Synthetic Biology: AI-powered tools and workflows supporting the design and engineering of biological systems for synthetic biology applications.
• Frontier Scientific Research: Capabilities supporting cutting-edge academic and institutional research across biological disciplines.

Customers, Validation, and Reach

• BioMap has supported more than 800 institutional users worldwide.
• More than 30 leading enterprises, including multinational corporations and Fortune Global 500 companies, rely on BioMap's platform.
• The system has been validated in more than 60 proof-of-concept (PoC) programs covering novel target discovery, antibody discovery, and innovative drug development.

BioMap continues to advance the frontier of AI-driven life science discovery, combining world-class foundation model technology with a comprehensive, modular platform to accelerate research and development across the global life sciences industry.